CORDHA study: Optimization of the viability of stem cells derived from umbilical CORd blood after maternal supplementation with docosahexaenoic acid (DHA) during the second or third trimester of pregnancy

Completed

• Conditions: Increase the quantity and viability of the stem cells, in the umbilical cord blood samples in pregnant women supplemented with DHA.; Pregnancy and Childbirth

• Registration Number: ISRCTN58396079
• Lead Sponsor: SmartBank (Italy)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-10-08
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 150

Inclusion Criteria

1. Age >18 years
2. Absence of: diabetes, hypertension or any other type of pathology requiring pharmacological therapy, genetic diseases, chromosome abnormalities and/or congenital malformations in the foetus and the absence of infectious disease (hepatitis B, hepatitis C, HIV and cytomegalovirus).

Exclusion Criteria

1. Age <18 years
2. Presence of: diabetes, hypertension or any other type of pathology requiring pharmacological therapy, genetic diseases, chromosome abnormalities and/or congenital malformations in the foetus and the presence of infectious disease (hepatitis B, hepatitis C, HIV and cytomegalovirus).
3. Cord blood samples with a volume of less than 80 ml and/or less than 70% cell vitality are excluded from the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified